Boston Scientific Slashes 2026 Growth Outlook Despite Strong Q1 Performance

Boston Scientific (BSX) has revised its financial projections for the 2026 fiscal year downward, signaling a slower growth trajectory for the remainder of the period. The company significantly reduced its net sales growth expectations, moving from a previous reported range of 10.5% to 11.5% down to a new estimate of 7.0% to 8.5%. Organic growth projections were similarly lowered to a range of 6.5% to 8.0%, compared to the previous 10.0% to 11.0%. Earnings per share (EPS) forecasts were also trimmed. The company now expects adjusted EPS to fall between $3.34 and $3.41, a decrease from the prior guidance of $3.43 to $3.49. Looking ahead to the second quarter of 2026, the firm anticipates reported net sales growth of 5.5% to 7.5% and adjusted EPS of $0.82 to $0.84. These lowered forecasts contrast with a strong start to the year. In the first quarter, Boston Scientific reported net sales of $5.203 billion, representing an 11.6% increase on a reported basis and a 9.4% increase on an organic basis. GAAP net income surged to $1.341 billion, or $0.90 per share, up from $674 million or $0.45 per share in the prior year. Adjusted EPS for the quarter was $0.80, compared to $0.75 a year ago. The guidance cut led to a slight decline in pre-market trading, with shares dipping 0.22% to $59.36. Investors are now weighing the strong Q1 momentum against the more conservative outlook for the full fiscal year.